The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global


Argos Therapeutics Awarded Patent

24-Aug-2015 | Source : AG-IP News | Visits : 5488
DURHAM, N.C. - Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis® technology platform, announced in a press release that it has been issued US Patent No. 9,085,807 by the United States Patent and Trademark Office. The issued claims relate to the company's AGS-004 product, which is currently being evaluated in an investigator initiated phase 2 clinical trial for the treatment of HIV infection. The patent will expire in 2026, excluding any possible patent term extensions.

HIV has a high mutation rate resulting in an infected individual carrying a mixture of many different variants. The ability of Argos' strain-independent amplification technology to produce large amounts of the vast array of variants from a small amount of blood or plasma allows the production of individualized immunotherapies matched to each patient's viral 'swarm.' This technology is used to manufacture AGS-004, an experimental immunotherapy for HIV, consisting of optimized dendritic cells electroporated with amplified RNA encoding HIV antigens which include a multitude of strain variants present for selected antigens.

"We are excited that the US Patent and Trademark Office has granted protection for this technology, which provides protection for our ability to customize immune responses to each patient's unique disease variants," said Charles Nicolette, chief scientific officer and vice president of research and development at Argos Therapeutics. "It adds to the continued strengthening of the immunotherapy opportunities using our proprietary Arcelis platform."

Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

Related Articles